Chronic administration of cannabidiol in man. Pilot study
Mincis, M.; Pfeferman, A.; Guimarães, R.X.; Ramos, O.L.; Zukerman, E.; Karniol, I.G.; Carlini, E.A.
Amb Revista da Associacao Medica Brasileira 19(5): 185-190
1973
ISSN/ISBN: 0102-843X PMID: 4543076 Document Number: 5083
Cannabis sativa (marihuana) is historically reported as having anti- convulsivant properties, but is hallucinogenic activity restricted clinical studies on this subject. In previous reports, it was verified that cannabidiol, one of the constituents of marihuana, had anti-epileptic actions in several animal surveys without producing toxic effects. In this pilot study, four normal volunteers, in a double-blind procedure, ingested 10mg daily of cannabidiol or placebo during 21 days were submitted to several neurological (including EEG), clinical (including ECG), psychiatric, blood and urine examinations. The authors verified that cannabidiol at the doses employed had no hallucinogenic properties and did not induce EEG, ECG, blood, urine, neurological or clinical alterations. The authors therefore conclude that the lack of toxic effects of cannabidiol in animals and human beings makes feasible it usage in clinical surveys.
Document emailed within 1 workday
